Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

References

• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973;33:3024–3028.
   PubMed Web of Science ®Google Scholar
• Habermann T, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009;27(15 Suppl.): Abstract 8509.
   Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a Bio-CORAL study. J Clin Oncol 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar
• Poeschel V, Nickelsen M, Hanel M, et al. Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of a phase-I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2006;108(Suppl. 1): Abstract 2738.
   Web of Science ®Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, et al. DA-EPOCH-R is highly effective in both BCL-6+and BCL-6− untreated de novo diffuse large B-cell lymphoma (DLBCL): study update and analysis of survival outcomes for multiple biomarkers. Blood 2006;108(Suppl. 1): Abstract 206.
   Web of Science ®Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, et al. Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma. Blood 2004;104(Suppl. 1): Abstract 159.
   Web of Science ®Google Scholar
• Fayad L, Pro B, Hagemeister F, et al. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features in patients younger than 60 years. Blood 2007;110(Suppl. 1): Abstract 1285.
   Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d’Etude Des Lymphomes De l’Adulte (GELA) Study LNH03-2B. Blood 2010;116(Suppl. 1): Abstract 109.
   Web of Science ®Google Scholar
• Vitolo U, Cabras MG, Rossi G, et al. Rituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as first line treatment in stage III-IV diffuse large B-cell lymphoma (DLBCL) at poor prognosis: final analysis of phase II GIMURELL trial. Blood 2006;108(Suppl. 1): Abstract 329.
   Google Scholar
• Borate U, Steciuk M, Alexander K, et al. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may overcome adverse prognosis in patients with diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) molecular profile. J Clin Oncol 2011;29(15 Suppl.): Abstract e18522.
   Google Scholar
• Nowakowski GS, Reeder CB, LaPlant B, et al. Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: a phase I/II study. J Clin Oncol 2011; 29(15 Suppl.): Abstract 8015.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Janik J, Gea-Banacloche J, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 2004;104(Suppl. 1):Abstract 1385.
   Web of Science ®Google Scholar
• Leonard JP, Furman RR, Cheung Y-KK, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood 2005;106(Suppl. 1): Abstract 491.
   Google Scholar
• Micallef INM, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011;118:4053–4061.
   PubMed Web of Science ®Google Scholar
• Hagemeister FB. Maintenance and consolidation strategies in non-Hodgkin's lymphoma: a review of the data. Curr Oncol Rep 2010;12:395–401.
   PubMedGoogle Scholar
• Pfreundschuh M, Held G, Zeynalova S, et al. Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2011;118: Abstract 592.
   Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B cell lymphomas (DLBCL) treated in randomized prospective salvage therapy, RICE or RDHAP followed by BEAM plus autologous stem cell transplantation (ASCT). A BioCORAL report. Blood 2011;118(Suppl. 1): Abstract 594.
   Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Nyman H, Holte H, et al. High serum vascular endothelial growth factor (VEGF) level is an adverse prognostic factor in high risk diffuse large B-cell lymphoma (DLBCL) patients treated with dose-dense chemoimmunotherapy and Systemic CNS prophylaxis. Results from a Nordic phase II study. Blood 2010;116(Suppl. 1): Abstract 4142.
   Google Scholar
• Maurer MJ, Micallef INM, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 2011;29:1620–1626.
   PubMed Web of Science ®Google Scholar
• Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010;116:e81–e89.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011;118: 1350–1358.
   PubMed Web of Science ®Google Scholar
• Li C, Kim S-W, Rai D, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009;113:6681–6690.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034–1040.
   PubMed Web of Science ®Google Scholar
• Lee N-R, Song E-K, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247–256.
   PubMed Web of Science ®Google Scholar
• Mato AR, Feldman T, Zielonka T, et al. R-HCVAD/R-MTX-Arac (R-HCVAD) overcomes risk features associated with inferior outcomes in the treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL). Blood 2010;116(Suppl. 1): Abstract 1782.
   Web of Science ®Google Scholar
• Purroy N, Bergua J, Gallur L, et al. Dose-adjusted EPOCH plus rituximab in untreated patients with poor prognosis large B-cell, with analysis of germinal center and activated B-cell biomarkers. A phase IV study conducted by the Spanish PETHEMA group. Blood 2011;118(Suppl. 1): Abstract 593.
   Google Scholar
• Purroy N, Lopez A, Vallespi T, et al. Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma. A phase2 study conducted by the Spanish PETHEMA group. Blood 2009;114(Suppl. 1): Abstract 2701.
   Google Scholar
• Molina TJ, Canioni D, Copie-Bergman C, et al. R-ACVBP benefits to younger patients with non-germinal centre diffuse large B-cell lymphoma as compared to R-CHOP in the GELA trial LNH03-2B. Blood 2011;118(Suppl. 1): Abstract 2632.
   Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547–561.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Wildes TM, Farrington L, Yeung CCS, et al. Hyper-CVAD and rituximab-hyperCVAD in Burkitt lymphoma (BL): a multi-institutional experience. J Clin Oncol 2011;29(15 Suppl.): Abstract e18541.
   Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar